CA
NZ
UK
AU
IND
US
TheNasdaqComposite is often described as a technology index, but a large slice of it is medicine. Drug developers, device makers and gene-therapy pioneers sit alongside the software names, and in September 2026 they span nearly the entire risk spectrum. Regeneron (NASDAQ:REGN) and LivaNova (NASDAQ:LIVN) …
Health care has long been one of the busiest neighbourhoods of theNasdaqComposite, and September 2026 finds it split between companies already generating real revenue and those still spending toward their first approvals. The five tickers here capture that spread. Tandem Diabetes Care (NASDAQ:TNDM), Tactile …
Biotechnology has always been the part of theNasdaqComposite where the extremes live. On any given day theindexcarries a $180-billion-plus commercial giant alongside clinical-stage companies whose entireMarket Valuerests on a single molecule and a single data readout.
TheNasdaqComposite is often shorthand for "tech," but it is also home to a sprawling healthcare cohort that runs from cash-generating pharmaRoyaltyholders to clinical-stage biotechs living quarter to quarter. Five of them, Innoviva (NASDAQ:INVA), Align Technology (NASDAQ:ALGN), Rocket Pharmaceuticals (NASDAQ:RCKT), Neurocrine Biosciences (NASDAQ:NBIX) and GRI …
Grouping five tickers under one headline is a convenience, not a thesis. Longeveron (NASDAQ:LGVN), DexCom (NASDAQ:DXCM), Grace Therapeutics (NASDAQ:GRCE), Prothena (NASDAQ:PRTA) and Phio Pharmaceuticals (NASDAQ:PHIO) share aNasdaqlisting and a healthcare label, and little else. One is a profitable, multi-billion-dollar device maker; three are clinical-stage …
Biotech rarely moves as a bloc. It moves as a collection of binary events, a trial readout here, a regulatory decision there, that happen to sit under the same index. That is exactly why Galectin Therapeutics (NASDAQ:GALT), Biogen (NASDAQ:BIIB), Corcept Therapeutics (NASDAQ:CORT), Kura Oncology …
TheNasdaqComposite is often reduced to its megacap technology names, yet a large slice of its membership is life sciences, companies whose fortunes turn on clinical data, regulatory decisions and cash runway rather than ad revenue or chip cycles. That makes the biotech corner of …
The five tickers in this headline share anindexand a sector label, and almost nothing else. Ascendis Pharma (NASDAQ:ASND) is a profitable, fast-growing endocrine and rare-disease company. Aurinia (NASDAQ:AUPH) sells a single lupus drug at scale and buys back stock. Ocugen (NASDAQ:OCGN) is pre-revenue but …
Biotech spent much of 2026 trying to prove it had left its multi-year drawdown behind. The five names in this headline are a useful cross-section of where the risk actually sits. Altimmune (NASDAQ:ALT) is chasing the crowded obesity and liver-disease market. Aura Biosciences (NASDAQ:AURA) …
● Celcuity won FDA approval for REVTORPYK (gedatolisib) on July 14, 2026 for a subset of HR+/HER2-, PIK3CA wild-type breast cancer, with shipments expected to begin late in the third quarter of 2026 and cash and investments of roughly $754.0 million.
Please wait processing your request...